System incorporates Neurostatus Definitions booklet into the electronic data entry process to improve rater accuracy and consistency.
WCG has launched an enhanced digital version of the Neurostatus-Expanded Disability Status Scale (EDSS) to capture clinical trial data. Collaborating with Neurostatus-UHB Ltd., a University Hospital Basel (UHB) subsidiary led by CEO Marcus D'Souza, M.D. and Chief Operating Officer Evy Fricker, the e-EDSS aims to improve data quality for an MS clinical trial endpoint.
While this new system is designed to enhance the rater's data entry experience, it was built to provide better data quality through the implementation of the Neurostatus proprietary scoring algorithms and edit checks, supporting the rater with real-time feedback on data inconsistencies. A web-based data review process has been incorporated into the new e-EDSS system to facilitate faster review and oversight of data quality.
D'Souza said in a press release, "Data entry is extremely fast and easy, given its almost identical replication of the paper form with which researchers are already very familiar. This system also uniquely incorporates the Neurostatus Definitions booklet into the electronic data entry process, and we cannot wait to quantify the direct impact this has on rater accuracy and consistency."
Reference: WCG Collaborates With Leading Multiple Sclerosis KOL to Launch Neurostatus-eEDSS System/PRNewswire
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.